Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer (Q33331271)

25 July 2017

title

Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer (English)

1 reference

25 July 2017

1 reference

6

A Le Cesne

0 references

author name string

M Spielmann

1

1 reference

25 July 2017

A Llombart

2

1 reference

25 July 2017

L Zelek

3

1 reference

25 July 2017

R Sverdlin

4

1 reference

25 July 2017

O Rixe

5

1 reference

25 July 2017

language of work or name

1 reference

1 December 1999

1 reference

25 July 2017

1 reference

25 July 2017

volume

10

1 reference

25 July 2017

issue

12

1 reference

25 July 2017

page(s)

1457-1460

1 reference

Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008318523058

7 January 2021

Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008318523058

7 January 2021

Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008318523058

7 January 2021

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008318523058

7 January 2021

Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008318523058

7 January 2021

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008318523058

7 January 2021

Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008318523058

7 January 2021

Cisplatin as first-line therapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008318523058

7 January 2021

Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008318523058

7 January 2021

Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008318523058

7 January 2021

Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008318523058

7 January 2021

Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008318523058

7 January 2021

A phase II trial of circadian-timed paclitaxel and cisplatin therapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008318523058

7 January 2021

Identifiers

DOI

10.1023/A:1008318523058

1 reference

25 July 2017

1 reference